Barclays’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Barclays’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,300	Closed	-$584K	–	4853
2021 Q3	$584K	Buy	+3,300	New	+$531K	﹤0.01%	3109
2019 Q2	–	Sell	-11,300	Closed	-$828K	–	7375
2019 Q1	$828K	Buy	+11,300	New	+$769K	﹤0.01%	3618

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Barclays's MRTX Position: Q1 2024 in Review

Barclays sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 492,345 shares — an estimated $28.9M sold.

Barclays first reported a position in MRTX in Q1 2014 and held it in 39 quarters. The position peaked at $28.9M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Barclays reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Barclays sold 492,345 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $28.9M.
Barclays first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2014 and held it in 39 quarters.
Barclays's Mirati Therapeutics, Inc. Common Stock position peaked at $28.9M in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Barclays's 13F filing for Q1 2024, filed 15 May 2024.